Facebook
Twitter
LinkedIn
Forward
Remission and Treatment Augmentation of Depression in the United States
Instructions
Click the REGISTER button to take the posttest.
Click here to return to the JCP CME article
Overview
Closer monitoring of symptoms through measurement-based care and setting symptom remission as a goal can help improve outcomes for adults with depression.
Read the whole article at psychiatrist.com here:
Remission and Treatment Augmentation of Depression in the United States
© Copyright 2021 Physicians Postgraduate Press, Inc.
Target Audience
Psychiatrists
Learning Objectives
Try evidence-based strategies such as augmentation when measurement-based care for depression indicates that patients have not achieved symptom remission
CME Background
Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.
CME Objective
After studying this article, you should be able to:
- Try evidence-based strategies such as augmentation when measurement-based care for depression indicates that patients have not achieved symptom remission
Statement of Need and Purpose
Treatment outcomes for depression are suboptimal in clinical practice, probably due in part to the lack of use of measurement-based care. Data collected over time with the same standardized assessment tools can help clinicians track which treatments allow patients to regain the ability to function at work and home, which treatments are not useful, and whether residual symptoms exist. Clinicians need education on the implementation of routine monitoring and the use of next-step strategies that may improve patient outcomes.
Release, Expiration, and Review Dates
This educational activity was published in October 2021 and is eligible for AMA PRA Category 1 Credit™ through December 31, 2023. The latest review of this material was October 2021.
Disclosure of Off-Label Usage
The authors have determined that, to the best of their knowledge, fluvoxamine, milnacipran, levomilnacipran, clomipramine, agomelatine, asenapine, lurasidone, olanzapine, paliperidone, risperidone, ziprasidone, thyroid hormone, lithium, lamotrigine, modafinil, lisdexamfetamine, and pramipexole are not approved by the US Food and Drug Administration for the treatment of major depressive disorder.
Funding/Support
None.
Additional Information
The original data set for the National Health and Nutrition Examination Survey (NHANES) is available from the website of the survey sponsored by the National Center for Health Statistics, Centers for Disease Control and Prevention (https://wwwn.cdc.gov/nchs/nhanes/).
Faculty Affiliation
Ramin Mojtabai, MD, PhD, MPH*
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, and Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
Masoumeh Amin-Esmaeili, MD, MPH
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, and Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran
Stanislav Spivak, MD
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, and Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
Mark Olfson, MD, MPH
Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, and New York State Psychiatric Institute, New York, New York
*Corresponding author: Ramin Mojtabai, MD, PhD, MPH, 624 N. Broadway, Room 797, Baltimore, MD 21205 (rmojtab1@jhu.edu).
Financial Disclosure
All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past 3 years, Marlene P. Freeman, MD, Editor in Chief of The Journal of Clinical Psychiatry, has received research funding from JayMac and Sage; has been a member of the Independent Data Safety and Monitoring Committee for Janssen (Johnson & Johnson) and Novartis; and has served on advisory boards for Eliem and Sage. As an employee of Massachusetts General Hospital (MGH), Dr Freeman works with the MGH National Pregnancy Registry, which receives funding from Alkermes, Aurobindo, AuroMedics, Johnson & Johnson/Janssen, Otsuka, Sage, Sunovion, Supernus, and Teva, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships.
Drs Mojtabai, Amin-Esmaeili, Spivak, and Olfson have no financial relationships relevant to this article to disclose.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation